Psyomics
Precision mental-health SaaS and bipolar biomarker platform from a Cambridge spin-out
| Deal Type | Equity |
|---|---|
| Sector | HealthTech & Digital Health |
| Geography | United Kingdom with planned US expansion |
| Stage / Vintage | Pre-Series A |
| Total Fundraise | GBP 5.0M |
| Minimum Ticket | N/D |
Opportunity Overview
Psyomics is a Cambridge spin-out developing beseen, a SaaS platform for mental-health referral, triage and assessment, alongside a longer-dated bipolar biomarker programme. Beseen integrates qualitative and quantitative patient data into dynamic clinical reporting and workflows, and is designed to support multiple mental health conditions, care settings and age groups. The deck states that the platform has been selected by NHS and private providers serving more than 8M lives and can deliver 5x productivity gains. The internal Bridge Partners screening memo views the company as promising but still venture-style, with the immediate commercial case in workflow software and the biomarker providing upside but adding clinical, regulatory and reimbursement risk.
Key Highlights
- Cambridge University spin-out with clinically led team and commercial healthcare experience.
- Beseen platform targets referral, triage, assessment and clinical workflow productivity.
- Selected by NHS and private providers serving more than 8M lives according to the deck.
- ARR milestones shown from GBP 370k in 2024 to GBP 1.0M forecast for 2025 and GBP 2.2M forecast for 2026.
- GBP 5.0M pre-Series A round, with GBP 2.0M committed from Parkwalk and Meridian referenced in the materials.
GCC Relevance
Thematic fit exists through healthcare digitisation, AI-enabled care pathways and mental-health access, but the internal screening memo notes that GCC fit is not self-evident without a clearer Middle East go-to-market plan, regional customer references and more diligence-ready financial disclosure.